Bibliografie tematiche / HCV

Indice

Articoli di riviste
Tesi
Libri
Capitoli di libri
Atti di convegni
Rapporti di organizzazioni

Letteratura scientifica selezionata sul tema "HCV"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 6 settembre 2023

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "HCV".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "HCV"

CRAMP, M. E. "HBV + HCV = HCC?" Gut 45, n. 2 (1 agosto 1999): 168–69. http://dx.doi.org/10.1136/gut.45.2.168.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Mujeeb, Syed Abdul, Qamar Jamal, Rafique Khanani, Nayyer Iqbal e Shahnaz Kaher. "Prevalence of Hepatitis B Surface Antigen and HCV Antibodies in Hepatocellular Carcinoma Cases in Karachi, Pakistan". Tropical Doctor 27, n. 1 (gennaio 1997): 45–46. http://dx.doi.org/10.1177/004947559702700117.

Testo completo

Abstract (sommario):

Hepatocellular carcinoma (HCC) is a common cancer the world over. In Pakistan it has an incidence of 8/100 000 per annum. To assess the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in biopsy proven cases of HCC a serological study was conducted at Screening Laboratory of Blood Transfusion Services, Jinnah Postgraduate Medical Centre. Of 54 sera of HCC tested for HBV and HCV infections, 67% showed HBV infection, and 33% HCV infection. Among them 24% were positive for both HBV and HCV infections. No HBV and HCV infection was found in 24% cases of HCC. Our findings suggest viral association for most of the HCC cases reported in the country. We suggest an immediate intervention strategy to prevent the spread of HBV and HCV infections by mandatory screening of blood for HBV and HCV infections, and the use of disposable/sterilized needles, instruments for all invasive procedures. For the prevention of vertical transmission of HBV infections all pregnant women should be screened and vaccinated and HBV vaccination should also be included in EPI (expanded programme for immunization).

Gli stili APA, Harvard, Vancouver, ISO e altri

Stroffolini, Tommaso, e Giacomo Stroffolini. "A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma". Cancers 15, n. 8 (20 aprile 2023): 2388. http://dx.doi.org/10.3390/cancers15082388.

Testo completo

Abstract (sommario):

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading cause of hepatocellular carcinoma (HCC) worldwide. Currently, HBV-related HCC predominates in Sub-Saharan Africa and South-East-Asia, while HCV-related HCC predominates in northern Africa and in the western world. Liver cirrhosis is the underlying condition in most HBV cases and in nearly all HCV cases. Several cofactors, viral and non-viral, play a role in the progression toward HCC: dual HBV/HCV infection, HDV, HIV, alcohol intake, smoking, diabetes mellitus, obesity, and NAFLD/NASH. HBV vaccine is effective in preventing both infection and HCC; antiviral drugs may suppress HBV replication and eradicate HCV infection, halting progression to HCC. Inequalities exist between high- and low-income countries with respect to vaccine availability and access to antivirals. These factors represent barriers to the control of HCC incidence. Lack of an effective vaccine against HCV is also a serious barrier to HCV elimination and HCC prevention. The most crucial steps and knowledge that have arisen over time on the association between the two major hepatotropic viruses and HCC are discussed in this historical review.

Gli stili APA, Harvard, Vancouver, ISO e altri

Huang, Yen-Tsung, Chin-Lan Jen, Hwai-I. Yang, Mei-Hsuan Lee, Jun Su, Sheng-Nan Lu, Uchenna H. Iloeje e Chien-Jen Chen. "Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C". Journal of Clinical Oncology 29, n. 27 (20 settembre 2011): 3643–50. http://dx.doi.org/10.1200/jco.2011.36.2335.

Testo completo

Abstract (sommario):

PurposeBoth hepatitis B (HBV) and C viruses (HCV) are causes of hepatocellular carcinoma (HCC), but lifetime risk and sex difference remain unclear. This study aimed to assess the lifetime risk and sex difference of HCC among patients with chronic HBV and/or HCV.MethodsA prospective cohort of 23,820 residents of Taiwan age 30 to 65 years were enrolled from 1991 to 1992, with 477 instances of HCC occurring subsequently. Serum samples collected at enrollment were tested for seromarkers and viral load of HBV and HCV. Newly developed HCC was ascertained through computerized data linkage with national cancer registry and death certification systems.ResultsThe cumulative lifetime (age 30 to 75 years) incidences of HCC for men and women positive for both HBV surface antigen (HBsAg) and antibodies against HCV (anti-HCV) were 38.35% and 27.40%; for those positive for HBsAg only, 27.38% and 7.99%; for those positive for anti-HCV only, 23.73% and 16.71%; and for those positive for neither, 1.55% and 1.03%, respectively. There was a significant male predominance in incidence of HCC for chronic HBV carriers but not for chronic carriers of HCV or both. Multivariate adjusted hazard ratio of developing HCC decreased with age in HBsAg-seropositive men but increased with age in anti-HCV–seropositive women. Among dual-infected participants, there was an inverse association between HBV and HCV viral load. Risk of HCC increased significantly with increasing viral load of HBV and HCV.ConclusionThere exists a suppressive effect of HCV on HBV viral load. Individual and combined effects of the two viruses on HCC vary with sex and age.

Gli stili APA, Harvard, Vancouver, ISO e altri

Pár, Alajos. "Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma". Orvosi Hetilap 150, n. 1 (1 gennaio 2009): 19–26. http://dx.doi.org/10.1556/oh.2009.28529.

Testo completo

Abstract (sommario):

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

Gli stili APA, Harvard, Vancouver, ISO e altri

Haberl, Elisabeth M., Thomas S. Weiss, Georg Peschel, Kilian Weigand, Nikolai Köhler, Josch K. Pauling, Jürgen J. Wenzel et al. "Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma". International Journal of Molecular Sciences 22, n. 10 (18 maggio 2021): 5297. http://dx.doi.org/10.3390/ijms22105297.

Testo completo

Abstract (sommario):

Hepatocellular carcinoma (HCC) still remains a difficult to cure malignancy. In recent years, the focus has shifted to lipid metabolism for the treatment of HCC. Very little is known about hepatitis B virus (HBV) and C virus (HCV)-related hepatic lipid disturbances in non-malignant and cancer tissues. The present study showed that triacylglycerol and cholesterol concentrations were similar in tumor adjacent HBV and HCV liver, and were not induced in the HCC tissues. Higher levels of free cholesterol, polyunsaturated phospholipids and diacylglycerol species were noted in non-tumorous HBV compared to HCV liver. Moreover, polyunsaturated phospholipids and diacylglycerols, and ceramides declined in tumors of HBV infected patients. All of these lipids remained unchanged in HCV-related HCC. In HCV tumors, polyunsaturated phosphatidylinositol levels were even induced. There were no associations of these lipid classes in non-tumor tissues with hepatic inflammation and fibrosis scores. Moreover, these lipids did not correlate with tumor grade or T-stage in HCC tissues. Lipid reprogramming of the three analysed HBV/HCV related tumors mostly resembled HBV-HCC. Indeed, lipid composition of non-tumorous HCV tissue, HCV tumors, HBV tumors and HBV/HCV tumors was highly similar. The tumor suppressor protein p53 regulates lipid metabolism. The p53 and p53S392 protein levels were induced in the tumors of HBV, HCV and double infected patients, and this was significant in HBV infection. Negative correlation of tumor p53 protein with free cholesterol indicates a role of p53 in cholesterol metabolism. In summary, the current study suggests that therapeutic strategies to target lipid metabolism in chronic viral hepatitis and associated cancers have to consider disease etiology.

Gli stili APA, Harvard, Vancouver, ISO e altri

Fang, Lily, Amanda Yu e Jane A. Buxton. "Identification of Acute Vaccine-Preventable Hepatitis in Individuals with Chronic Hepatitis in British Columbia between 1991 and 2007". Canadian Journal of Infectious Diseases and Medical Microbiology 22, n. 1 (2011): 10–14. http://dx.doi.org/10.1155/2011/564290.

Testo completo

Abstract (sommario):

BACKGROUND: In British Columbia (BC), hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccines are provincially funded for persons with chronic hepatitis infections. PURPOSE: To assess the effectiveness of BC public health follow-up of HBV and hepatitis C virus (HCV) cases and immunization policy by determining the number of vaccine-preventable acute hepatitis infections reported following a chronic HBV or HCV diagnosis, by examining demographic characteristics and by observing temporal trends.METHODS: All newly identified cases of HAV, HBV and HCV between 1991 and October 2007 were extracted from the BC integrated Public Health Information System and linked to ascertain cases of hepatitis suprainfection.RESULTS: Between 1991 and October 2007, 30 BC residents with chronic HBV and 104 with HCV were subsequently diagnosed with HAV. Acute HBV was identified in 162 persons previously diagnosed with HCV. Significantly more men than women developed hepatitis suprainfection (P<0.0001), but women were of a younger age when they were diagnosed with HAV (P=0.02) and acute HBV (P=0.0002). HAV suprainfection cases among those with HCV peaked in 1998 at 33 cases and declined to zero cases in 2007. In comparison, HBV suprainfection among individuals with chronic HCV peaked in 1996 at 26 cases and declined to two cases in 2007.DISCUSSION: Cases of HAV and acute HBV have declined among HCV-infected individuals. However, despite the availability of publicly funded vaccines for high-risk groups, a substantial number of acute HBV infections post-HCV identification are still identified, indicating that follow-up and vaccination coverage should be improved in these populations.

Gli stili APA, Harvard, Vancouver, ISO e altri

Buxton, Jane A., e Jin Hee Kim. "Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations". Canadian Journal of Infectious Diseases and Medical Microbiology 19, n. 2 (2008): 197–202. http://dx.doi.org/10.1155/2008/410362.

Testo completo

Abstract (sommario):

In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and international recommendations.RESULTS: Persons with chronic HCV respond well to HAV vaccine, but studies exploring HBV vaccine efficacy in this population have equivocal results. Vaccine schedules and participant characteristics differ among studies, and most do not adjust for confounders. Some studies found no difference in HBV vaccine response between patients with chronic HCV and controls. However, HBV vaccine response was generally reduced in those with cirrhosis and HCV genotype 1. Organizations recommend HAV and HBV vaccines for persons with chronic HCV, but do not suggest alterations in schedule or dose.RECOMMENDATIONS: Because HAV vaccine response is good and routine laboratory testing may not detect lower levels of vaccine-induced anti-HAV, the standard HAV vaccine schedule is recommended without postimmunization testing. HBV vaccine should be administered early in the course of chronic HCV infection because response may be lower in patients with cirrhosis. Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. Determination of postimmunization hepatitis B surface antibody, especially in patients with cirrhosis or genotype 1, will allow HBV vaccine boosters to be offered.

Gli stili APA, Harvard, Vancouver, ISO e altri

Shen, Yu-Chuan, Hui-Ching Hsu, Tzu-Min Lin, Yu-Sheng Chang, Li-Fang Hu, Lung-Fang Chen, Sheng-Hong Lin et al. "H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection". Journal of Clinical Oncology 40, n. 11 (10 aprile 2022): 1206–19. http://dx.doi.org/10.1200/jco.21.01802.

Testo completo

Abstract (sommario):

PURPOSE H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS Patients with HBV, HCV, or dual HBV-HCV infection were enrolled from Taiwan's National Health Insurance Research Database and examined for the period from January 1, 2006, to December 31, 2015. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the association between AH use and HCC risk. RESULTS We included patients with HBV infection (n = 521,071), HCV (n = 169,159), and dual HBV-HCV (n = 39,016). Patients with HBV, HCV, or dual virus infection who used AHs exhibited significantly lower risk of HCC relative to patients who did not use AH, with their adjusted hazard ratio being 0.489 (95% CI, 0.455 to 0.524), 0.484 (95% CI, 0.450 to 0.522), and 0.469 (95% CI, 0.416 to 0.529), respectively. Furthermore, there was a dose-response relationship between AH use and the risk of HCC in the HBV cohort. The adjusted hazard ratios were 0.597 (95% CI, 0.530 to 0.674), 0.528 (0.465 to 0.600), 0.470 (0.416 to 0.531), and 0.407 (0.362 to 0.457) for AH use of 28-42, 43-63, 64-119, and ≥ 120 cumulative defined daily doses, respectively, relative to no AH use. Additionally, there was also a dose-response relationship between AH use and the risk of HCC in the HCV and dual HBV-HCV cohorts. CONCLUSION AH use may reduce the risk for HCC among patients with HBV, HCV, or dual infection in a dose-dependent manner. Further mechanistic research is needed.

Gli stili APA, Harvard, Vancouver, ISO e altri

Alhamadany, Alaa Younis Mahdy, e Wajdi Sabeeh Sadek. "Analysis of the Chromosomal Aberrations in Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Hepatocellular Carcinoma Patients (HCC) in Mosul City, Iraq". NTU Journal of Pure Sciences 1, n. 2 (31 maggio 2022): 48–53. http://dx.doi.org/10.56286/ntujps.v1i2.210.

Testo completo

Abstract (sommario):

Abstract. Hepatocellular carcinoma (HCC) (also known as liver cancer) is one of the most frequent cancers in humans. HCC is linked to chronic hepatitis B and C virus infection, cirrhosis, and excessive alcohol consumption. The aim of this study was to use Metaphase chromosome analysis in whole blood to determine chromosomal aberrations (CA) in HBV, HCV, and HCC patients. A cohort of 145 samples have been collected from participants from the date of 5 \ 1 \ 2020 to 15\9\ 2021. Among those samples are (40 healthy controls, HBV 38, 44 HCV, and HCC 23) to make cytogenetic evaluation by observing the analysis of chromosome aberration. Our study showed that the chromosome aberration With Gap was higher in the HCC patient group followed by HBV patient group. also, the results showed that of the chromosome aberration without Gap in the HCC, and HCV patient groups were significantly higher in females than in males. the results showed that higher break, DIC was in HBV patients group followed by HCV patients group. the results showed that deletion, and ace were higher in the HCV and HCC patient group followed by HBV patient group. Finally with RO. Trans., the results showed that ace was higher in the HCV, and HBV patient groups. In conclusion, we indicate that HBV, HCV, and HCC patients have chromosomal instability because of their chromosome aberration levels.

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Tesi sul tema "HCV"

Soares, Sampaio Aletheia. "Marcadores sorológicos para os vírus da hepatite B e C em pacientes HIV-positivos atendidos no Hospital Universitário Oswaldo Cruz". Universidade Federal de Pernambuco, 2005. https://repositorio.ufpe.br/handle/123456789/7445.

Testo completo

Abstract (sommario):

Made available in DSpace on 2014-06-12T18:32:19Z (GMT). No. of bitstreams: 2 arquivo8105_1.pdf: 1882884 bytes, checksum: e39c1a843287ccbea7f187b84dbe1593 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2005
A ocorrência de co-infecção pelo HIV e hepatites B e C tem sido relatada desde a era- HAART (do inglês Highly Active Antinetrovial Therapy), quando a mortalidade nas pessoas infectadas pelo HIV começou diminuir. Como conseqüência do fato de terem as mesmas rotas de transmissão, a co-infecção do HBV ou HCV em pessoas infectadas pelo HIV tem aumentado e tornou-se um problema de saúde pública. No Brasil, a prevalência média da coinfecção HIV e hepatites, encontrada pelo Ministério da Saúde é em torno de 40%, com a maioria em grupos de usuários de drogas. Freqüências variáveis de co-infecção têm sido relatadas, dependendo da população e da região estudada. O objetivo principal deste estudo foi identificar a freqüência de marcadores sorológicos para hepatite B e C em pacientes infectados pelo HIV, acompanhados em um hospital escola e os possíveis fatores associados à presença de tais marcadores. Quatrocentos e vinte e nove pacientes foram estudados, de ambos os sexos e com idade variando entre 18 a 77 anos. Os participantes respondiam um questionário específico, com características sócio-demográficas e tinham uma amostra de sangue testada para os marcadores HBsAg, Anti-HBc total e Anti-HCV, utilizando a técnica MEIA-Axym-Abbott. A freqüência encontrada de marcadores foi 10,3% para o HBsAg, 38,7% para o Anti-HBc total e 10,7% para o Anti-HCV. Dentre os pacientes, 1,4% possuíam tanto HBsAg quanto Anti-HCV positivos. Não houve associação significante estatisticamente entre as variáveis parceiro homossexual, uso de drogas endovenosas, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão e a infecção pelo HBV, expressa pela positividade do HBsAg. A única variável que mostrou associação com infecção pelo HBV foi uso de drogas inalatórias. Nenhuma destas variáveis, incluindo, parceiro homossexual, uso de drogas endovenosas, uso de drogas inalatórias, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão tiveram associação significativa estatisticamente com a presença do Anti-HCV. Este estudo encontrou freqüências comparáveis com outros relatados no Brasil, mas com freqüências de coinfeccção menores que aqueles das regiões Sul e Sudeste. Entretanto, nenhuma associação específica com comportamentos de risco foi encontrada neste estudo, mostrando importante diferença quando comparado com estudos realizados em outras regiões do Brasil

Gli stili APA, Harvard, Vancouver, ISO e altri

Burke, Stephanie. "Generalized Impairment of CD8+ T-cells in HCV Mono- and HIV-HCV Co-infection". Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32770.

Testo completo

Abstract (sommario):

Chronic hepatitis C virus (HCV) infection has global effects on the immune system. CD8+ T-cells, responsible for viral clearance and control, are dysfunctional for as yet unknown reasons. It is hypothesized that IL-7 signaling pathway deficiencies contribute to this impairment. Blood-derived CD8+ T-cells in chronic HCV mono- and HIV-HCV co-infection had lower IL-7-induced activation of STAT5 and production of Bcl-2, and lower proliferation in co-infection, compared to controls. Lower Bcl-2 production was also associated with increased fibrosis. These changes were independent of the IL-7 receptor α expression and suppressor of cytokine signaling 1 or 3 expression. Intrahepatic CD8+ T-cells in HCV-infection did not activate STAT5 above basal levels with cytokine stimulation and had lower Bcl-2 expression than blood-derived cells. In conclusion, bulk CD8+ T-cells were impaired in response to IL-7 and the IL-7 signaling pathway may be one mechanism by which CD8+ T-cells are impaired in chronic HCV infection.

Gli stili APA, Harvard, Vancouver, ISO e altri

Kleefeld, Felix [Verfasser]. "Untersuchung des Einflusses einer Interferon-freien HCV-Eradikation auf neurokognitive Funktionen in HIV/HCV-koinfizierten und HCV-monoinfizierten Patienten / Felix Kleefeld". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2019. http://d-nb.info/1179778103/34.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Gupta, Priyanka. "Host gene expression and its regulation by microRNA in HCV and HIV/HCV co-infection". Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/11998.

Testo completo

Abstract (sommario):

HCV infection is prevalent and long-term infection may lead to liver cirrhosis and hepatocellular carcinoma (HCC). HIV/HCV co-infection has been shown to accelerate progression of HCV associated liver disease, and HCV in exacerbating hepatotoxicity of antiretroviral therapy. Both viruses are able to manipulate the host gene expression (mRNA) and regulatory (miRNA) machinery. It remains unclear how the regulation of mRNA expression is governed in HCV-infected Peripheral Blood Mononuclear Cells (PBMC) and liver tissue (tumor and non-tumor). This may help explain the cross-talk between PBMC and liver for predicting early events guiding the development of cirrhosis and HCC. Differentially expressed (DE) genes and miRNAs in each group comparison were also validated by Polymerase Chain reaction (PCR). We identified significant interactions between the DE miRNAs and genes with Bayesian network analysis. Selected miRNA: mRNA interactions were validated with the dual luciferase reporter assay that showed negative regulatory effect on the gene targets. Overall, this study has helped to not only define the utility of PBMCs in predicting early genomic events guiding cirrhosis and HCC in liver tissue in HCV-infected patients, but also showed evidence for mono and co-infection specific genes and miRNAs, which may help develop new generation of biomarkers for prognosis.

Gli stili APA, Harvard, Vancouver, ISO e altri

RUSSO, DARIO. "Diagnosi parallela automatizzata di infezioni virali trasmissibili per via ematica (HIV, HCV, HBV)". Doctoral thesis, Università degli Studi di Milano, 2007. http://hdl.handle.net/2434/33618.

Testo completo

Abstract (sommario):

Automated parallel diagnosis of viral infections transmitted in haematic tract. The aim of this study was to develop a complete system for the identification and quantification of HBV, HCV, HIV using molecular biological techniques by means of Real Time PCR. The first step was to develop a positive control, valid for all considered viruses, absolutely free from risk of infection due to the fact that they are synthetic clones. The second step of this study was to develop a complete kit in basic PCR with detection by gel electrophoresis, to identify specific sequences of viral genomes. This test uses a solid thermopolimers mix which allows retrotranscription and amplification to be performed separately in a single vial. The third step was to develop a complete kit in real time PCR to quantify the viral concentrations using, in a first phase, a simple liquid mix and, in a second phase, a solid thermopolimers mix. At the end of my ph.D study it was produced a complete system containing a positive control to check the system and to make a real time standard curve. The real innovation of this study was the development of a solid master mix that delivers a rapid but highly specific test for the 3 viruses simultaneous

Gli stili APA, Harvard, Vancouver, ISO e altri

Souza, Iury Oliveira. "Validação de ensaio imunocromatográfico para a detecção múltipla de anticorpos específicos contra HIV, HBV e HCV". reponame:Repositório Institucional da UFBA, 2013. http://www.repositorio.ufba.br/ri/handle/ri/11787.

Testo completo

Abstract (sommario):

Submitted by Hiolanda Rêgo (hiolandar@gmail.com) on 2013-06-10T18:28:37Z No. of bitstreams: 1 Dissertação_ICS_Iury Souza.pdf: 1047267 bytes, checksum: 06bc8acdb629b7e8ae63feab201995ad (MD5)
Made available in DSpace on 2013-06-10T18:28:37Z (GMT). No. of bitstreams: 1 Dissertação_ICS_Iury Souza.pdf: 1047267 bytes, checksum: 06bc8acdb629b7e8ae63feab201995ad (MD5)
CAPES
Cerca de 33,3 milhões de pessoas apresentam infecção pelo Human Immunodeficiency Virus (HIV) no mundo; 180 milhões estão infectados pelo Hepatitis C Virus HCV e estima-se que 360 milhões apresentem infecção ativa pelo Hepatitis B Virus (HBV). Outra realidade mundial é a co-infecção entre esses vírus. Os dados mostram a importância global dessas viroses e a urgência do desenvolvimento de novos ensaios de diagnóstico sensíveis, específicos, rápidos e de baixo custo, que possam atender à demanda de entidades públicas inseridas em programas para prevenção e diagnostico dessas doenças. O presente trabalho consiste em validação relativa de um novo teste imunocromatográfico desenvolvido pela empresa canadense Medmira para detecção de anticorpos específicos contra HIV, HCV e HBV. Os resultados encontrados foram extremamente favoráveis para a detecção de anticorpos específicos para HIV, apresentando 98,6% de sensibilidade e 100% de especificidade. Para o anti-HBV a sensibilidade e especificidade encontradas foram de 90,0% e 98,6%, e de 86,3% e 100%, para anti-HCV, respectivamente. Nenhuma reatividade cruzada foi encontrada e a reprodutibilidade e repetitividade foram de 100%. O índice kappa e a acurácia global do teste foram de 0,91 (0,88-0,94) e 95,5% (93,5-97,5), respectivamente. Conclui-se que o ensaio imunocromatográfico é clinicamente útil em triagens rápidas para detecção de anticorpos anti-HIV, HCV e HBV.
Salvador

Gli stili APA, Harvard, Vancouver, ISO e altri

Heller, Sophie [Verfasser]. "Untersuchung visueller Aufmerksamkeitsparameter vor und nach einer Hepatitis C (HCV)-Therapie mit Direct Antiviral Agents bei HCV-monoinfizierten und HCV/HIV-koinfizierten Patienten / Sophie Heller". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2020. http://d-nb.info/1206186070/34.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Hultgren, Catharina. "Immune modulation in chronic HBV and HCV infection /". Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4255-2/.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Costa, Cintia Bezerra Almeida. "Polimorfismo do HLA-G na coinfecção HIV/HCV". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-21052014-181750/.

Testo completo

Abstract (sommario):

O objetivo geral da pesquisa foi associar os polimorfismos do gene HLA-G (região 3\' NT) com a coinfecção HIV/HCV e com os grupos (HIV, HCV e controles saudáveis). Trata-se de um estudo transversal, comparativo, descritivo. Participaram do estudo, 560 indivíduos, sendo 156 controles saudáveis, 102 coinfetados HIV/HCV, 186 infectados pelo HIV e 116 por HCV. Para a identificação dos polimorfismos, o DNA genômico foi extraído do sangue total e a genotipagem feita por PCR e visualizada em gel de poliacrilamida a 7%, no qual o polimorfismo de 14pb foi identificado, e por sequenciamento os outros sete SNPs. Os resultados sociodemográficos apontam que a amostra na sua grande maioria foi composta por indivíduos adultos e do sexo masculino. No que diz respeito à cor da pele, na comparação entre os grupos HCV e HIV/HCV, observou-se um maior número de coinfectados apresentando a cor preta e parda do que nos monoinfectados (P=0,0001). Com relação à categoria de exposição para aquisição do HIV, na comparação entre os grupos HIV e HIV/HCV, observou-se diferença significante na transmissão por via heterossexual, sendo sua frequência maior no grupo HIV (P=0,0000). No caso da comparação entre os grupos HCV e HIV/HCV, observou-se também diferença na transmissão heterossexual, sendo sua frequência significantemente maior no grupo HIV/HCV (P=0,0001). Quanto aos achados relacionados ao genótipo do HCV, na comparação entre os grupos HCV e HIV/HCV, o genótipo 1a apresentou frequência maior nos coinfectados (P=0,0001). No que diz respeito à carga viral do HIV, na comparação entre os grupos HIV e HIV/HCV, o grupo da monoinfecção apresentou maior carga viral do que o grupo da coinfecção (P=0,0350). Com relação ao grau de fibrose hepática, na comparação entre os grupos HCV e HIV/HCV, o grupo da coinfecção tem mais fibrose leve do que o grupo da monoinfecção (P=0,0009). Quanto aos polimorfismos genéticos da região 3\' NT do HLA-G, foi encontrado que o genótipo de heterozigose Del/Ins de 14 pb apresentou diferença significante nos indivíduos coinfectados pelo HIV/HCV (P=0,0216) quando comparados com o grupo controle. Em relação ao SNP +3003, a comparação dos grupos HCV e controle saudável mostrou que alelo +3003T apresentou uma frequência significantemente maior no grupo HCV (P=0,0147); o genótipo +3003C/T apresentou uma frequência maior no grupo controle (P=0,0095); o genótipo +3003T/T estava maior no grupo HCV (P=0,0095). A comparação entre os grupos HIV e HCV mostrou que a frequência do alelo +3003C estava maior no grupo HIV (P=0,0463); e o genótipo +3003T/T apresentou uma frequência maior no grupo HCV (P=0,0494). A frequência do genótipo +3187A/A estava maior no grupo HIV/HCV em comparação ao HIV (P=0,0193); e do +3187A/G estava maior no grupo HIV (P=0,0187). O genótipo +3196C/G apresentou frequência significamente maior no grupo HIV do que no controle saudável (P=0,0213). A UTR-10, na comparação entre os grupos HIV e controle, mostrou frequência maior no grupo HIV (P=0,0044); quando comparados os grupos HIV/HCV e HIV, frequência foi maior no grupo HIV (P=0,0300) e na comparação entre os grupos HIV e HCV, sua frequência também foi maior no grupo HIV (P=0,0140). A UTR-4, na comparação dos grupos HCV e controle saudável, revelou uma frequência maior no grupo controle (P=0,0147). A UTR-9, na comparação dos grupos HIV/HCV e HIV, mostrou frequência maior no grupo HIV/HCV (P=0,0460). Em relação aos dados clínicos, a presença do alelo T na posição +3035 foi significantemente associada à maior carga viral do HCV, acima de 400.000 cópias/mL (P=0,0244). Em relação aos tipos de genótipos do HCV, a presença do alelo +3027C foi associada ao subtipo 1a do HCV (P=0,0109). Adicionalmente, a presença do genótipo C/C na posição +3027 também foi significantemente associada com o subtipo 1a do HCV (P=0,0015). Ainda, o alelo A do SNP +3187 foi significantemente associado com os outros genótipos do HCV, excluindo o 1a (P=0,0369). Embora não esteja totalmente esclarecida a função do gene HLA-G, estudos têm sido desenvolvidos para melhor elucidar sua função nos contextos fisiológicos, como gestação, e patológicos, como tumores, transplantes, doenças inflamatórias e infecciosas. Tais estudos procuram ampliar o conhecimento sobre o sistema imunológico e contribuem para o desenvolvimento de novas estratégias diagnósticas e terapêuticas. Os resultados do presente estudo contribuem para a ampliação do conhecimento sobre os polimorfismos da região 3\' NT do gene HLA-G, na coinfecção HIV/HCV. Como também, na melhoria da assistência de enfermagem que deve buscar reduzir a morbimortalidade pela referida patologia. Porém, ainda há um longo percurso a ser percorrido na compreensão dos fatores imunogenéticos envolvidos na coinfecção pelo HIV/HCV
The general objective of the research was to associate the polymorphism of the gene HLA-G (region 3\' NT) with the co-infection HIV/HCV and with the groups (HIV, HCV and healthy control). It is a cross-sectional, comparative, descriptive study. 560 individuals participated of the study, being 156 healthy control individuals, 102 co- infected HIV/HCV, 186 infected by HIV and 116 by HCV. For identifying the polymorphisms, the genomic DNA was extracted from the total blood and the genotyping was made by PCR and visualized in gel of polyacrylamide at 7%, in which the polymorphism of 14pb was identified, and by sequencing the other seven SNPs. The social demographic results point that the most of the sample was composed by male adult individuals. Regarding the color of the skin, in the comparison between the groups HCV and HIV/HCV, a bigger number of co-infected with black skin and brown-skinned was observed than in the mono infected (P=0,0001). Regarding to the category of exposition for acquisition of the HIV, in the comparison between the groups HIV and HIV/HCV, a significant difference was observed in the transmission through heterosexual exposition, being its frequency bigger in the group HIV (P=0,0000). In the case of the comparison between the groups HCV and HIV/HCV, the difference in the heterosexual transmission was also observed, being its frequency significantly higher in the group HIV/HCV (P=0,0001). About the finding related to the genotype of the HCV, in the comparison between the groups HCV and HIV/HCV, the genotype 1a presented higher frequency in the co- infected (P=0,0001). Regarding to the viral load of the HIV, in the comparison between the groups HIV and HIV/HCV, the group of the mono infection presented bigger viral load that the group of the co-infection (P=0,0350). Regarding to the level of hepatic fibrosis, in the comparison between the groups HCV and HIV/HCV, the group of co-infection has a lighter fibrosis that the group of the mono infection (P=0,0009). Regarding to the genetic polymorphisms of the region 3\' NT of the HLA-G, it was found that the genotype of heterozygosis Del/Ins of 14 pb, presented significant difference in the individuals co-infected by the HIV/HCV (P=0,0216) when compared with the control group. About the SNP +3003, the comparison of the groups HCV and healthy control, it was showed that the allele +3003T presented a significant higher frequency in the group HCV (P=0,0147); the genotype +3003C/T presented a higher frequency in the control group (P=0,0095); the genotype +3003T/T was bigger in the group HCV (P=0,0095). The comparison between the groups HIV and HCV showed that the frequency of the allele +3003C was bigger in the group HIV (P=0,0463); and the genotype +3003T/T presented a bigger frequency in the group (P=0,0494). The frequency of the genotype +3187A/A was bigger in the group HIV/HCV in comparison to the HIV (P=0,0193); and of the +3187A/G was bigger in the group HIV (P=0,0187). The genotype +3196C/G presented frequency significantly bigger in the group HIV than in the healthy control (P=0,0213). The UTR-10, in comparison between the groups HIV and control, showed bigger frequency in the group HIV (P=0,0044); when compared the groups HIV/HCV and HIV, frequency was bigger in the group HIV (P=0,0300) and in the comparison between the groups HIV and HCV, its frequency was also bigger in the group (P=0,0140). The UTR-4, in the comparison of the groups HCV and healthy control, revealed a bigger frequency in the control group (P=0,0147). The UTR-9, in comparison of the groups HIV/HCV and HIV, showed bigger frequency in the group HIV/HCV (P=0,0460). Regarding to the clinical data, the presence of the allele T in the position +3035, was significantly associated to bigger viral load of the HCV, above 400.000 copies /mL (P=0,0244). About the types of genotypes of the HCV, the presence of the allele +3027C was associated with the subtype 1a of the HCV (P=0,0109). Additionally, the presence of the genotype C/C in the position +3027 was also significantly associated with the subtype 1a of the HCV (P=0,0015). Still, the allele A of the SNP +3187 was significantly associated with the other genotypes of the HCV, excluding the 1a (P=0,0369). Although the function of the gene HLA-G, is not totally clarified, studies have been developed for better elucidate its function in the physiological contexts, like gestation, and pathological, such as tumours, transplants, infectious and inflammatory diseases. These studies aim to extend the knowledge about the immunological system and contribute for the development of new diagnostic and therapeutic strategies. The results of this study contribute for enhancement of the knowledge about the polymorphisms of the region 3\' NT of the gene HLA-G, in the co-infection HIV/HCV. As well as, in the improvement of the assistance of nursing that must seek reducing the morbid mortality by the pathology referred. However, there is still a long path to be followed in the comprehension of the immunogenic factors involved in the co-infection by the HIV/HCV

Gli stili APA, Harvard, Vancouver, ISO e altri

Uccellini, L. "HOST GENETIC INFLUENCE ON HIV AND HCV INFECTIONS". Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/215587.

Testo completo

Abstract (sommario):

In patients with chronic hepatitis C, the hepatitis C virus (HCV) RNA level is an important predictor of treatment response. To explore the relationship of HCV RNA with viral and demographic factors, as well as IL28B genotype, we examined viral levels in an ethnically diverse group of injection drug users (IDUs). Between 1998 and 2000, the Urban Health Study (UHS) recruited IDUs from street settings in San Francisco Bay area neighborhoods. Participants who were positive by HCV EIA were tested for HCV viremia by a bDNA assay. HCV genotype was determined by sequencing the HCV NS5B region. For a subset of participants, IL28B rs12979860 genotype was determined by Taqman. Among 1701 participants with HCV viremia, median age was 46 years and median duration of injection drug use was 26 years; 56.0% were African American and 34.0% were of European ancestry (non-Hispanic). HIV-1 prevalence was 13.9%. The overall median HCV RNA level was 6.45 log10 copies/ml. In unadjusted analyses, higher levels were found with older age, male gender, African American ancestry, HBV infection, HIV-1 infection and IL28B rs12979860-CC genotype; compared to participants infected with HCV genotype 1, HCV RNA was lower in participants with genotype 3 or genotype 4. In an adjusted analysis, age, gender, racial ancestry, HIV-1 infection, HCV genotype and IL28B rs12979860 genotype were all independently associated with HCV RNA. The level of HCV viremia is influenced by a large number of demographic, viral and human genetic factors. HIV The clinical course of HIV-1 infection is highly variable among individuals, at least in part as a result of genetic polymorphisms in the host. Toll-like receptors (TLR) play a crucial role in the host’s innate immunity and may influence HIV-1 disease progression. The transcription factor IRF-5 is an important player in the TLR-MyD88 signaling cascade. We investigated the impact of two SNPs in TLR9 gene, rs352139 and rs352140, and two SNPs in IRF5 gene, rs10954213 and rs11770589, on CD4 count, HIV viral load, and clinical progression in a cohort of HIV-infected patients. Two SNPs in TLR9 and IRF5 are in linkage disequilibrium and rs352140GA TLR9 was associated with the rapid progressors phenotype: for rs352140 GG+GA versus AA, P = 0.025, OR= 0.5479, confidence interval (CI) 0.31-0.97. No other association was found between TLR9 and IRF5 SNPs and viral load, CD4 count or other clinical data. Rapid progression of HIV-1 infection was associated with TLR9 polymorphisms. Because of its potential implications for intervention strategies and vaccine developments, additional epidemiological and experimental studies are needed to confirm this association.

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Libri sul tema "HCV"

Thiemann, Lillian. Double jeopardy: The HIV/HCV co-infection handbook. New York: Community Prescription Service, 1999.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Dammacco, Franco, a cura di. HCV Infection and Cryoglobulinemia. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-1705-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Dammacco, Franco. HCV Infection and Cryoglobulinemia. Milano: Springer-Verlag Italia, 2012.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Musharraf, Husain, e Population Council (Bangladesh), a cura di. Prevalence of HIV, HBV, HCV and syphilis markers in pregnant women of Bangladesh. Dhaka, Bangladesh: Population Council, 1997.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Okita, Kiwamu, a cura di. HCV and Related Liver Diseases. Tokyo: Springer Japan, 1999. http://dx.doi.org/10.1007/978-4-431-68488-6.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Jürgens, Ralf. HIV/AIDS and HCV in prisons: A select annotated bibliography. Ottawa, Ont: International Affairs Directorate, Health Canada, 2005.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Okita, Kiwamu, a cura di. HCV/Oxidative Stress and Liver Disease. Tokyo: Springer Japan, 2003. http://dx.doi.org/10.1007/978-4-431-67005-6.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Kiwamu, Okita, a cura di. HCV/oxidative stress and liver disease. Tokyo: Springer, 2003.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

name, No. HCV/oxidative stress and liver disease. Tokyo: Springer, 2003.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Sofia, Michael J., a cura di. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28400-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Capitoli di libri sul tema "HCV"

Vachon, Marie-Louise C., Alicia C. Stivala e Douglas T. Dieterich. "HIV/HCV and HIV/HBV Co-infections". In Mount Sinai Expert Guides: Hepatology, 78–95. Oxford, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118748626.ch7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Weiner, Amy J., Michael M. Thaler, Kevin Crawford, Joe Kansopon, Keith Ching, J. Eric Hall, Fang Hu, David Chien e Michael Houghton. "HCV-positive, HIV-1-negative Mothers Transmit HCV". In Viral Hepatitis and Liver Disease, 463–67. Tokyo: Springer Japan, 1994. http://dx.doi.org/10.1007/978-4-431-68255-4_118.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Coffin, Carla S., e Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfection". In Hepatitis B Virus and Liver Disease, 239–62. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4843-2_13.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Zhou, Kali, e Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfections". In Hepatitis B Virus and Liver Disease, 339–73. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-3615-8_15.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Terrault, Norah A. "Hepatic Transplantation and HBV, HCV, and HIV Infections". In Sherlock's Diseases of the Liver and Biliary System, 758–80. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119237662.ch38.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Salmon-Ceron, Dominique, J. E. Arends, C. Leoni, C. Solas e G. Peytavin. "HIV/HCV Coinfection: Current Challenges". In Viral Hepatitis: Chronic Hepatitis C, 141–57. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Perez-Alamino, Rodolfo. "Hepatitis Arthritis: HBV and HCV". In Infections and the Rheumatic Diseases, 107–12. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23311-2_10.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Ingiliz, Patrick, Maud Lemoine e Yves Benhamou. "Chronic HCV and HIV Coinfection". In Chronic Hepatitis C Virus, 75–91. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Pereira, Luis F., John J. Faragon, Antoine Douaihy e Courtney E. Kandler. "Treatment of Comorbid HIV/HCV". In HIV Psychiatry, 477–97. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-80665-1_18.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Beard, Michael R. "HCV Replication". In Advanced Therapy for Hepatitis C, 1–11. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444346343.ch1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "HCV"

BUZUTTI, P. C., e F. M. T. BINHARDI. "IMPLICAÇÕES DA CO-INFECÇÃO DA DENGUE EM PACIENTES CRONICAMENTE INFECTADOS PELOS VÍRUS HBV E HCV NA REGIÃO DE SÃO JOSÉ DO RIO PRETO-SP". In III Mostra Dos Trabalhos De Conclusão De Curso Da Especialização Em Vigilância Laboratorial Em Saúde Pública. Agron Science, 2022. http://dx.doi.org/10.53934/101021-2.

Testo completo

Abstract (sommario):

Dengue é uma doença tropical febril aguda de extrema importância para a saúde pública. Outro importante agravo são as hepatites virais, que se manifestam de forma aguda ou crônica e infectam milhões de pessoas. As manifestações da dengue em uma população com alta prevalência de HBV e HCV foram pouco estudadas, apesar de estudos mostrarem que uma co-infecção entre elas pode mascarar ou complicar os sintomas. Neste estudo avaliou-se as manifestações e evoluções clínicas em pacientes portadores de HBV e HCV, co-infectados com DENV na região de S. J. Rio Preto-SP, entre 2009 a 2016. Foram comparados os dados de 502 pacientes com HBV e 1.388 com HCV com planilhas do Sinan que continham dados de pacientes com DENV. Após identificar os pacientes co-infectados, investigou-se a carga viral do HBV e HCV pré e pós infecção por DENV e a evolução do quadro clínico. Pacientes com HCV apresentaram maior taxa de co-infecção e diversidade de sintomas, enquanto que o aumento da carga viral ocorreu mais em pacientes com HBV. Não foram observadas diferenças significativas entre gênero e alteração das dosagens de TGO e TGP em ambas co-infecções. O DENV-1 foi o único sorotipo detectado e nenhuma evolução para dengue grave ou óbito.

Gli stili APA, Harvard, Vancouver, ISO e altri

Darvishian, Maryam, Carmine Rossi, Stanley Wong, Amanda Yu, Jason Wong, Jane Buxton, Mark Gilbert et al. "P386 Cancer risk among people with HIV, HBV and/or HCV infections". In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.481.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Ferreira da Silva, Giovanna, Marcello do Couto Dias, Irley Karoline Seixas Paiva, Mércia Ferreira Ribeiro, Katarine Antonia dos Santos Barile e Carlos Eduardo de Melo Amaral. "AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C". In Congresso Brasileiro de Inovação em Microbiologia. Congresse.me, 2022. http://dx.doi.org/10.54265/rnfk1700.

Testo completo

Abstract (sommario):

INTRODUÇÃO: A detecção de HCV na triagem, em doadores de sangue da Fundação Hemopa, é realizada simultaneamente por um teste sorológico e um teste molecular. No caso de discordância entre estes, é realizado um teste confirmatório. Geenius HCV Supplemental Assay é utilizado como teste confirmatório suplementar para análise da presença de anticorpos específicos para HCV, utilizando os antígenos específicos NS3, NS4, NS5 e capsídeo. OBJETIVO: Determinar a freqüência de resultado de imunocromatografia Geenius HCV Confirmatory Assay (BioRad) em amostras Eclesys Anti-HCV reagentes (positivos e inconclusivos) e teste de ácido nucléico (NAT) para HCV indetectáveis. MATERIAIS E MÉTODOS: Foram avaliadas 55 amostras entre o período de Setembro de 2021 a Março de 2022. Para este estudo, todas as amostras selecionadas apresentaram sorologia Anti HCV reagente (valor de leitura da amostra/ valor de “cut off” (S/CO) >0,8) e NAT indetectável. Foram utilizados, para detecção de anticorpos anti-HCV, o ensaio Eclesys Anti-HCV com metodologia de eletroquimioluminescência, e para detecção de material genético de HCV, o Kit NAT HIV/HCV Bio-Manguinhos com metodologia de PCR em tempo real. A realização do teste Geenius HCV Supplemental Assay se dá de acordo com a utilização da proteína A de ligação ao anticorpo, conjugada com partículas coloridas de celulose e os antígenos específicos ligados à membrana da fita. Como resultado, pode haver a captura dos anticorpos Anti-HCV, produzindo uma reação colorimétrica na área teste do cassete e na área de controle da reação. RESULTADOS: Conforme o ensaio sorológico Eclesys Anti-HCV, de 55 amostras, 32,8% (17/55) apresentaram resultado de sorologia inconclusivo (valor de “cut off” (S/CO) 0,8 a 1,2) e 67,2% (37/55) apresentaram resultado de sorologia positivo (valor de “cut off” (S/CO) > 1,2) . Entre as amostras que tiveram resultado de sorologia inconclusiva, 100% (17/17) apresentaram resultados de imunocromatografia negativos. Entre as amostras que tiveram sorologia positiva, 97,2% (36/37) apresentaram resultados de imunocromatografia negativos e 2,8% (1/37) apresentaram resultados de imunocromatografia indeterminados. Não houveram resultados positivos.CONCLUSÃO: A imunocromatografia mostrou-se ferramenta eficiente para confirmar a não exposição ao HCV em 98% (54/55) dos doadores de sangue com resultados discordantes do teste de triagem sorológico-molecular para o HCV, permitindo que os doadores recebessem a devida orientação. PALAVRAS-CHAVE: HCV, IMUNOCROMATOGRAFIA, TESTE

Gli stili APA, Harvard, Vancouver, ISO e altri

Yarraguntla, Nireekshith, Naveena Tirumala, Syed Shameem e K. srinivasa rao. "Detection of Hepatitis viruses (HBV, HAV, HCV) in serum using MEMS based Bio-Sensor". In 2018 Second International Conference on Computing Methodologies and Communication (ICCMC). IEEE, 2018. http://dx.doi.org/10.1109/iccmc.2018.8487679.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Corinaldesi, G., R. Sentinelli, S. Guglielmi, V. Barocci, S. Castelletti, I. Pierantonelli, S. Gemini, A. Riva, M. Martini e A. Costantini. "CP-059 Efficacy and cost of direct acting antivirals for the treatment of hcv infection among HCV monoinfected and HIV/HCV coinfected patients in real life setting". In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.58.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rocha, Daniele, Elisabete Andrade, Marcela Fontana, Marisa Ribeiro, Elaine Motta, Daniela Godoy, Antonio Ferreira, Rodrigo Brindeiro, Amilcar Tanuri e Patricia Alvarez. "Desenvolvimento de uma nova partícula calibradora para o Kit NAT HIV/HCV/HBV Bio-Manguinhos". In III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2016. http://dx.doi.org/10.35259/isi.sact.2016_27367.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Kudrjavtseva, E. N., M. I. Korabelnikova, T. A. Semenenko, Ya V. Panasyuk e S. N. Kuzin. "THE IMPORTANCE OF ANTI-HCV SCREENING IN PATIENTS OF LARGE MULTIFIELD HOSPITALS". In Molecular Diagnostics and Biosafety. Federal Budget Institute of Science 'Central Research Institute for Epidemiology', 2020. http://dx.doi.org/10.36233/978-5-9900432-9-9-49.

Testo completo

Abstract (sommario):

In the studied cohort, HCV subtypes 1b and 3a prevailed — 47,7% and 38,9%, respectively HCV genotype 2 was detected in 7,2% of cases and HCV subtype 1a — in 5,8% of cases. HCV genotype was not determined in 0,4% of patients. Difference between a frequency of detection of subtypes 1b and 3a of HCV in men and women were recorded. Subtype 3a HCV was determined in men in 44,8% of cases, and in women — in 31,7% of cases (p < 0.01). HCV subtype 1b in women was determined with a higher frequency (55,0%, р < 0, 01), than in men (41,8%).

Gli stili APA, Harvard, Vancouver, ISO e altri

Wu, Xindong. "The HCV induction algorithm". In the 1993 ACM conference. New York, New York, USA: ACM Press, 1993. http://dx.doi.org/10.1145/170791.170825.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Farias, Bruna Brandão de, Imman Fuad Khattab Hassan, Camila Tlustak Soares e Maristela Böhlke. "Crioglobulinemia associada ao HCV". In 13º Congresso Gaúcho de Clínica Médica. São Paulo: Editora Edgard Blücher, 2016. http://dx.doi.org/10.5151/medpro-xiiicgcm-1459187062.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Prasetyo, Afiono Agung. "VLPs of HCV local isolates for HCV immunoassay diagnostic approach in Indonesia". In INTERNATIONAL CONFERENCE ON ENGINEERING, SCIENCE AND NANOTECHNOLOGY 2016 (ICESNANO 2016). Author(s), 2017. http://dx.doi.org/10.1063/1.4968353.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rapporti di organizzazioni sul tema "HCV"

Hung, Hsuan-Yu, e Chung-Yu Chen. The impact of Sofosbuvir/Velpatasvir/Voxilaprevir treatment on serum hyperglycemia in HCV infections: A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, dicembre 2021. http://dx.doi.org/10.37766/inplasy2021.12.0109.

Testo completo

Abstract (sommario):

Review question / Objective: To assess the possible cause of events, the incidence of grade 3 hyperglycemia after treating Sofosbuvir/Velpatasvir/Voxilaprevir in HCV infections. Condition being studied: Sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) is an effective, safe rescue therapy regimen for patients have previously been treated failure. Initiating Direct-Acting Antiviral (DAA) treatment for HCV infection with diabetes have experienced hypoglycemia, it could improve insulin resistance due to clean HCV. However, some studies shown that SOF/VEL/VOX has Grade 3 hyperglycemia adverse events. This finding contradicts that other DAAs studies. Information sources: Conducting a comprehensive literature search on the pubmed, Cochrane, clinicalkey, Embase, and MEDLINE electronic databases.

Gli stili APA, Harvard, Vancouver, ISO e altri

Miller, Sarah, Autumn Spight, Mahogany Freeman e Sharon Little. Monitoring Adherence to HCV Screening Among the Baby Boomer Population. University of Tennessee Health Science Center, maggio 2022. http://dx.doi.org/10.21007/con.dnp.2022.0040.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Mensch, Barbara, e Erica Soler-Hampejsek. Characteristics associated with HIV and HSV-2 among adolescents in Malawi. Population Council, 2017. http://dx.doi.org/10.31899/hiv6.1007.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Mensch, Barbara, e Erica Soler-Hampejsek. Rates of HIV and HSV-2 among young people in Machinga, Malawi. Population Council, 2017. http://dx.doi.org/10.31899/hiv6.1027.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Smith, Lynette M., Nicholas A. Hein e Danstan S. Bagenda. Cash transfers and HIV/HSV-2 prevalence: a replication of a cluster randomized trial in Malawi. International Initiative for Impact Evaluation (3ie), ottobre 2017. http://dx.doi.org/10.23846/rps0012.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Yu, Fang, Nicholas A. Hein e Danstan S. Bagenda. Preventing HIV and HSV-2 through improving knowledge and attitudes: a replication study of a multicomponent intervention in Zimbabwe. International Initiative for Impact Evaluation (3ie), marzo 2018. http://dx.doi.org/10.23846/rps0016.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rinke, Helen Mae. HCM Interface. Office of Scientific and Technical Information (OSTI), aprile 2020. http://dx.doi.org/10.2172/1617344.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Pinter, Abraham. HIV Vaccines Based on Novel MULV-HIV Fusion Proteins. Fort Belvoir, VA: Defense Technical Information Center, luglio 1999. http://dx.doi.org/10.21236/ada373677.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Bingamon, Brian Michael. HIV Mosaic Vaccine. Office of Scientific and Technical Information (OSTI), dicembre 2019. http://dx.doi.org/10.2172/1581247.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Kanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, luglio 1999. http://dx.doi.org/10.21236/ada367779.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!